Disc Medicine, Inc. IRON 深 滬
等待開盤 05-19 09:30:00 美东时间
66.85
-0.010
-0.01%
華盛通- 最 高69.725
- 今 開69.725
- 成交量 58.22万股
- 最 低 65.78
- 昨 收 66.86
- 總市值 25.54亿
- 52周最高 99.50
- 市盈率 靜 --
- 換手率 1.52%
- 52周最低 40.0001
- 委 比 48.51%
- 總股本 3819.91万
- 歷史最高 190.85
- 量 比 0.87
- 振 幅 5.90%
- 歷史最低 11.60
- 每 手 1
- 風險率 12.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
Shares of biotech-related companies are trading higher after reports suggesting that President Trump may fire FDA Commissioner Dr. Marty Makary.
Shares of biotech-related companies are trading higher after reports suggesting...
05-09 01:29
财报速睇 | Disc Medicine, Inc. 2026财年Q1营收0.00亿美元，同比增长0.0%；归母净利润亏损0.64亿美元，同比亏损扩大86.3%
华盛资讯5月5日讯，Disc Medicine, Inc.公布2026财年Q1业绩，公司Q1营收0.00亿美元，同比增长0.0%，归母净利润亏损0.64亿美元，同比亏损扩大86.3%。
05-05 20:49
Disc Medicine Q1 EPS $(1.65) Beats $(1.73) Estimate
Disc Medicine (NASDAQ:IRON) reported quarterly losses of $(1.65) per share which beat the analyst consensus estimate of $(1.73) by 4.62 percent. This is a 61.76 percent decrease over losses of $(1.02) per share from the
05-05 20:37
Disc Medicine To Present Data From RALLY-MF Phase 2 Trial Of DISC-0974 In Anemia Of Myelofibrosis In Oral Abstract Session At ASCO Annual Meeting
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases,
04-21 22:05
Disc Medicine Doses Last Patient In Pivotal Phase 3 APOLLO Study Of Bitopertin In Erythropoietic Protoporphyria
Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases,
03-27 04:32
Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria
Disc Medicine announced the completion of enrollment in its pivotal Phase 3 APOLLO trial for bitopertin in erythropoietic protoporphyria (EPP), with the study size expanded to 183 participants due to high demand. Results are expected in Q4 2026, with plans for an FDA submission and a decision anticipated by mid-2027. Bitopertin, an investigational glycine transporter 1 inhibitor, aims to address unmet needs in EPP treatment.
03-26 20:30
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
Truist Securities Maintains Buy on Disc Medicine, Lowers Price Target to $83
Truist Securities analyst Danielle Brill maintains Disc Medicine (NASDAQ:IRON) with a Buy and lowers the price target from $114 to $83.
02-28 01:37
